From Allergy Relief to Viral Defense? Exploring Nasal Antihistamine Use Against COVID
A recent phase 2 clinical trial suggests that azelastine nasal spray, a common antihistamine used for allergic rhinitis, may reduce the risk of SARS CoV 2 infection. Researchers observed lower infection rates and fewer symptomatic cases among participants using the spray. Although these early findings are intriguing, larger studies are needed before azelastine can be recommended for routine COVID prevention.